Retapamulin


Concise Prescribing Info
Indications/Uses
Impetigo and other bacterial skin infections due to meticillin-susceptible Staphylococcus aureus and Streptococcus pyogenes.
Dosage/Direction for Use
Adult : Topical As 1% oint: Apply twice daily for 5 days. Total treatment area: ≤100 cm2 total body surface area.
Dosage Details
Topical/Cutaneous
Bacterial skin infections due to methicillin-susceptible Staphylococcus aureus, Bacterial skin infections due to Streptococcus pyogenes, Impetigo
Adult: As 1% ointment: Apply onto affected area bid for 5 days. Re-evaluate if there is no response after 3 days of treatment. Total treatment area: ≤100 cm2 total body surface area.
Child: As 1% ointment: ≥9 mth: Apply onto affected area bid for 5 days. Total treatment area: ≤2% of total body surface area.
Contraindications
Hypersensitivity.
Special Precautions
Discontinue use if skin irritation occurs. Prolonged use may result in fungal or bacterial superinfection. Re-evaluate if there is no response within 3 days. Children <9 mth. Pregnancy, lactation.
Adverse Reactions
Headache, pyrexia, pruritus, eczema, diarrhoea. Application site irritation, pain, erythema, contact dermatitis.
Action
Description: Retapamulin is a pleuromutilin antibacterial isolated from the fungus Clitopilus passeckerianus. It is a bacteriostatic agent that works by inhibiting biosynthesis of bacterial protein by binding at protein L3 on the ribosomal 50S subunit. It also inhibits peptidyl transfer and blocks P-site interactions at this site, thus preventing the formation of active 50S ribosomal subunits.
Pharmacokinetics:
Absorption: Topical admin: Only very small amounts are absorbed into the systemic circulation.
Distribution: 94% bound to plasma proteins.
Metabolism: Extensively hepatically metabolised by mono-oxygenation and di-oxygenation to multiple metabolites.
Storage
Store between 15-30°C.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Retapamulin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in